title: [Noticeable clinical response to S-1/CDDP combination therapy for Virchow node recurrence after surgery for advanced gastric carcinoma with marked involvement of the esophagus - report of a case].
abstract: We have recently experienced a case in which S-1/CDDP combination therapy proved remarkably efficacious for a rapid, extensive lymph node recurrence with metastasis into a Virchow node that had developed after resection of advanced gastric carcinoma accompanied with a marked invasion of the esophagus. The patient, a woman aged 73, underwent a total gastrectomy upon left thoracolaparotomy for a gastric carcinoma at the cardia with a 5-cm involvement of the esophagus. On day 65 post-operation, a diagnosis of Virchow node and para-aortic lymph node recurrence was made on the basis of CT scan findings. Of tumor markers checked, CEA and CA19-9 were noted to be increased to as high as 37.55 ng/mL and 3,235 U/mL, respectively. The patient received three courses of S-1/CDDP combination therapy, with a consequent noticeable contraction of the Virchow node and enlarged para-aortic lymph node. Further, she was given two courses of S-1 therapy, which resulted in normalization of tumor markers. The patient has since been on continued chemotherapy without any sign of recurrence.
authors.affiliation: Dept. of Surgery, JR Sendai Hospital.
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Sugawara
authors.forename: Masataka
authors.initials: M
authors.lastname: Ichiki
authors.forename: Keijyou
authors.initials: K
authors.lastname: Sai
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kamata
authors.forename: Makoto
authors.initials: M
authors.lastname: Ansai
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Nakano
authors.forename: Masashi
authors.initials: M
authors.lastname: Kawamura
authors.forename: Azusa
authors.initials: A
authors.lastname: Ichinose
authors.forename: Shukichi
authors.initials: S
authors.lastname: Miyazaki
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002945:Cisplatin / Q000627:therapeutic use*; D004338:Drug Combinations; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D005773:Gastroscopy; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D012008:Recurrence; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin